|1.||Gräfe, Susanna: 11 articles (08/2015 - 05/2007)|
|2.||Guillemin, François: 10 articles (05/2015 - 09/2002)|
|3.||Bezdetnaya, Lina: 8 articles (05/2015 - 07/2003)|
|4.||Hopper, Colin: 7 articles (09/2013 - 08/2004)|
|5.||Stewart, Fiona A: 7 articles (06/2007 - 02/2003)|
|6.||Baas, Paul: 7 articles (06/2007 - 02/2003)|
|7.||Kiesslich, Tobias: 6 articles (11/2015 - 06/2007)|
|8.||Tan, I Bing: 6 articles (10/2013 - 07/2003)|
|9.||Stewart, F A: 6 articles (09/2012 - 04/2001)|
|10.||Foster, Thomas H: 6 articles (09/2011 - 09/2002)|
04/01/1999 - "Biodistribution data showed that the tumor selectivity of cMAb U36-conjugated mTHPC was increased in comparison with free mTHPC, despite the fact that conjugates with a higher mTHPC:MAb ratio were more rapidly cleared from the blood. "
10/01/2010 - "A fractionated double-injection protocol of mTHPC with 24-h and 3-h drug-light intervals (DLI) yielded 100% tumor cure, with tumors presenting a massive apoptosis of neoplastic cells along with a distortion of vessels. "
01/01/2015 - "Our study indicates a higher plasma peak concentration, a longer circulation time and a better tumor-to-skin ratio than those of Foslip®, another liposomal mTHPC formulation. "
11/01/2011 - "This review traces the development and study of the second-generation photosensitizer 5,10,15,20-tetra(m-hydroxyphenyl)chlorin through to its acceptance and clinical use in modern photodynamic (cancer) therapy. "
10/01/1999 - "We conclude that this tumor model may be used for the study of new pelvic debulking techniques, and that the tumor selectivity of PEG-m-THPC is exceptionally high 8 days after drug application. "
|2.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
09/01/2003 - "This paper demonstrates the efficacy of a second-generation photosensitizer, Foscan, in the primary treatment of a wide range of mucosal head and neck squamous cell carcinomas. "
10/15/2005 - "To examine the pharmacokinetics of liposomal m-THPC, we determined tissue and plasma variables in feline patients with spontaneous squamous cell carcinoma. "
08/10/2004 - "mTHPC offers an effective alternative treatment for early oral squamous cell carcinoma. "
12/01/2001 - "Twenty-five patients with squamous cell carcinoma (SCC) of the lip (Tis, T1, T2/N0/M0) and Karnofsky status > or = 70 received 0.15 mg/kg Foscan intravenously, followed 4 days later by a single non-thermal illumination of the tumour (light dose 20 J/cm2, irradiance 100 mW/cm2, lambda=652 nm). "
04/01/1999 - "To test the in vivo behavior of the mTHPC-MAb conjugates, the head and neck squamous cell carcinoma-selective chimeric MAb U36 was used in head and neck squamous cell carcinoma-bearing nude mice. "
|3.||Phototoxic Dermatitis (Phototoxicity)
11/01/2011 - "The efficiency of cellular uptake of Fospeg was reduced by 30-40% with respect to m-THPC in standard solution causing a slight reduction of the phototoxicity but without serious impairment of the efficacy of the treatment. "
02/14/2011 - "After release the ((1)O(2)) generation as well as the phototoxicity are more efficient compared with mTHPC applied without the HSA nanoparticles."
12/02/2010 - "Dark toxicity, phototoxicity and intracellular localization of mTHPC were studied. "
09/02/2010 - "Similar in vitro characteristics and phototoxicity were observed for Fospeg, the water-soluble formulation of mTHPC. "
09/01/2004 - "To examine the relationship between intrinsic phototoxicity and intracellular mTHPC content, we expressed cell survival as a function of cellular fluorescence. "
|4.||Head and Neck Neoplasms (Head and Neck Cancer)
03/01/2004 - "Patients with advanced cancer of the head and neck, who have exhausted other treatment options, can achieve significant clinical benefit and improvement in quality of life with mTHPC."
08/01/2007 - "The photosensitizing drug Foscan is licensed in the EU for the treatment of advanced head and neck cancer. "
10/01/2013 - "MR and CT based treatment planning for mTHPC mediated interstitial photodynamic therapy of head and neck cancer: description of the method."
03/01/2013 - "A systematic review was performed by searching seven bibliographic databases on database specific mesh terms and free text words in the categories; "head and neck neoplasms", "Photodynamic Therapy" and "Foscan". "
06/17/2011 - "The second generation photosensitizer mTHPC was approved by the European Medicines Agency (EMA) for the palliative treatment of advanced head and neck cancer in October 2001. "
01/01/2004 - "Modality of cell death induced by Foscan-based photodynamic treatment in human colon adenocarcinoma cell line HT29."
01/13/2003 - "Foscan subcellular localisation in the MCF-7 human adenocarcinoma cell line has been studied by means of confocal microscopy and microspectrofluorometry. "
04/01/2002 - "Photodynamic effects of mTHPC on human colon adenocarcinoma cells: photocytotoxicity, subcellular localization and apoptosis."
05/01/1998 - "In order to determine the consequences of photobleaching of fluorescing mTHPC material on cellular uptake and photocytotoxicity, human HT29 colon adenocarcinoma cells were incubated with photobleached mTHPC during 5 h with or without following irradiation with the fixed fluence. "
03/01/1999 - "The onset of action of pegylated mTHPC seemed slower but significantly exceeds that of mTHPC by days 3 and 4 with the greatest difference being noted at day 4. Pegylated mTHPC also induced significantly larger photonecrosis than mTHPC in squamous cell xenografts but not in adenocarcinoma at day 4, where mTHPC showed greatest activity. "
|4.||Dihematoporphyrin Ether (Porfimer Sodium)
|5.||Photosensitizing Agents (Photosensitizers)
|6.||Polyethylene Glycols (Polyethylene Glycol)
|8.||Aminolevulinic Acid (Levulan)
|1.||Photochemotherapy (Photodynamic Therapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)
|4.||Palliative Care (Palliative Medicine)